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Abstract
In a three-step protocol involving regioselective enzymatic acylation, per-O-trimethylsilylation, 
and a one-pot α-glycosidation/deprotection sequence, cholesteryl 6-O-tetradecanoyl-α-D-
glucopyranoside (α-CAG) of Helicobacter pylori is afforded starting from glucose in an overall 
yield of 45%. The production of CAG can be scaled to make purified quantities available to the 
bilogical community for the first time.
It is increasingly clear that membrane-bound cholesterol plays an important regulatory role 
in pathogenic processes. For example, cholesterol has been shown to modulate glycolipid 
conformations, which can either inhibit or facilitate recognition processes involving raft-
associated proteins.1 There is also recent evidence that cholesterol may directly mask 
glycosphingolipids such as monosialotetrahexosylganglioside (GM1) and thereby protect the 
carbohydrate from recognition by toxin-derived proteins including cholera toxin.2 When one 
considers these findings in the context of the discovery that many pathogenic bacteria 
produce enzymes that require extrusion of cholesterol from host cells, an intriguing interplay 
of cholesterol transport emerges.
Nowhere is the game more evident than in Helicobacter pylori infection.3,4 It is estimated 
that over 50% of the world’s population is infected with H. pylori4 a bacterium that resides 
in the mucosa of the stomach. Although H. pylori infection often goes undetected, chronic 
infection can lead to gastric ulcers or even cancer.5-11 Imbedded in the cell wall of H. pylori 
is a glycosyl transferase that combines uridine diphosphate glucose with host derived 
cholesterol to make cholesteryl-α-D-glucopyranoside (CG).8,9 Recent studies suggest that 
through a still unknown mechanism, H. pylori is able to sense cholesterol rich regions in 
host epithelial tissue and extract cholesterol from the host membrane for incorporation into 
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α-CG and two other CGs modified at the C-6 hydroxyl of glucose.12 One analog is 
acetylated with tetradecanoic acid and is referred to as α-CAG (1) (Figure 1), the other is 
phosphorylated and abbreviated as α-CPG. Together these three glycolipids make up 
approximately 25% of the lipid content of H. pylori and are a distinguishing feature of these 
bacteria.8,9
To date, biological studies involving CG, CAG and CPG have mostly relied upon natural 
sources, which furnish a mixture of all three glycolipids making it difficult to determine the 
independent roles of each consituent.10,11 To facilitate glycolipidomic profiling studies, we 
have initiated a synthetic campaign directed towards a streamlined synthesis of cholesteryl 
glycosides. An earlier reported synthesis of α-CG required a series of 8 steps starting from 
free glucose and the key step used Lewis acid promoted glycosylation to yield 75% of a 1:1 
α:β mixture of CG.13 However, no known synthetic procedure has generated α-CAG and a 
more direct route to cholesteryl glycosides would be advantageous.
For the past few years, we have been developing one-pot glycosylation strategies that 
capitalize on the unique reactivity of glycosyl iodides.14 We have found that 
trimethylsilyloxy protecting groups increase the reactivity of glycosyl iodides to the extent 
that even deactivated or hindered acceptors can be efficiently glycosidated.15 The overall 
reaction typically involves reacting a per-O-trimethylsilylated sugar with 
iodotrimethylsilane (TMSI) to generate the iodide in situ, followed by addition of an 
acceptor and acid aqueous work-up to remove the silyl protecting groups. This transient 
protecting group stategy is efficient but it is not without complications when trying to couple 
less reactive acceptors, such as cholesterol. In these cases, we find that a side reaction occurs 
and the acceptor becomes silylated, which leads to diminished yields. We reasoned that 
transilylation may be occurring from iodide attack on the primary C-6 trimethylsilyl group 
generating TMSI in situ, which subsequently reacts with cholesterol (Figure 2).
In targeting α-CAG, we decided to explore a chemoenzymatic synthesis wherein the C-6 
acyl group would first be incorporated using a lipase enzyme (Figure 3). We were hopeful 
that per-O-silylation of the resulting ester would proceed uneventfully, and that glycosyl 
iodide glycosylation would proceed more smoothly with an acyl group at C-6 rather than the 
more labile silyl group.
Previous work with lipase B from Candida antarctica provided powerful precedent for our 
strategy. In one study, Schmid and co-workers reacted glucose with a fatty acid donor in 
acetone or 2-butanone under reduced pressure using a soxhlet extractor for the removal of 
water.16 Under these conditions, high yields of 6-O-acyl glucose analogs were obtained. 
Later, these researchers investigated similar transformations on solid support.17 Presently, 
resin bound lipase B from Candida antarctica (Novozym 435) is commercially available 
and we decided to explore using this form of the enzyme to effect a similar transformation. 
Employing vinyl esters has proven advantageous, as the release of acetaldehyde acts as an 
internal water scavenger and alleviates the need to azeotrope. Novozym 435 has also been 
shown to work well in a variety of organic solvents, but portrays poor to no activity in DMF 
or pyridine.17 The enzyme activity however can be maintained at a high level by combining 
pyridine with a co-solvent. Earlier work illustrating that enzyme activity is inversely 
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proportional to the ratio of pyridine to co-solvent18 led us to use a 4:1 ratio of 
tetrahydrofuran (THF) to pyridine, which gave decent solubility properties of free glucose. 
After testing this solvent system with relatively large amounts of enzyme (1 μmol of glucose 
per mg of enzyme, Table 1, entry 1), optimization of the enzymatic acylation reaction was 
carried out varying the amount of vinyl ester and the quantity of enzyme.
Experiments showed that the amount of enzyme could be significantly reduced without 
affecting the yield. Eventually we found that approximately 90 μmol of glucose per mg of 
enzyme could be converted to 6-O-tetradecanoyl-D-glucopyranoside (2) with high yields 
(Table 1, entry 5). In contrast, the amount of vinyl ester employed was impactful (Table 1, 
entry 7 & 8). At least three equiv. of vinyl tretradecanoate were required to achieve efficient 
conversion (Table 1, entry 6). Upon scaling up to >250 mg, the enzymatic regioselective 
acylation became quantitative. It is important to note that the enzyme reaction requires 
sufficient mixing and must be void of all water to proceed efficiently. Thus, glucose was 
dried in a vacuum oven for 48 h prior to use and the reaction was carried out on a microplate 
thermoshaker at 40 °C.
After obtaining 2, the remaining glucosyl hydroxyl groups were protected using 
chlorotrimethylsilane (TMSCl) in pyridine and catalytic 4-N,N-dimethylaminopyridine 
(DMAP) to afford 6-O-tetradecanoyl-per-O-trimethylsilyl glucopyranoside (3) in 
quantitative yield (Scheme 1). The one-pot glycosidation protocol relies upon in situ 
generation of the α-iodide (4) using iodotrimethylsilane (TMSI) in chloroform. Initial 
formation of 4 was monitored via proton nuclear magnetic resonance (1H NMR) for the 
disappearance of the anomeric proton in compound 3 at δ 5.17 ppm and the appearance of 
the anomeric proton in 4 δ 6.73 ppm. To our surprise, 3 reacted very slowly with TMSI 
taking approximately 5 h in deuterated chloroform to generate 4. The long reaction time 
necessary to form 4 could be attributed to aggregation and micelle formation preventing 
significant exposure of the anomeric position. Consistent with this hypothesis, the 1H NMR 
signals were broadened in deuterated chloroform. Upon complete conversion of 3 to 
generate 4, the one-pot glycosidation/deprotection procedure was carried out using 
microwave assistance at 110 °C for 2 h followed by deprotection with Dowex50WX8-200 
acidic resin in methanol to afford 1 (Scheme 1). Interestingly, the reaction also proceeded in 
the absence of tetrabutylammonium iodide (TBAI) to give the desired α-linked product in 
approximately the same yield although the stereochemical outcome was only 6:1 in favor of 
the α-product rather than 8:1 in the presence of TBAI.
Glycolipid bioactivity is often correlated with anomeric steroechemistry. Thus, 
stereoselective synthetic methods capable of preparing highly pure anomers is necessary for 
the advancement of glycolipid research. With this in mind, we investigated the possibility of 
expanding the chemoenzymatic approach to include the synthesis of β-CAG, which has 
distinct biological properties relatvie to α-CAG and has been shown to increase 
phagocytosis of bacteria.5,8 Much to our delight, activation of the glycosyl iodide (4) with 
silver triflate afforded β-CAG in 57% yield (1:6 α:β), after aqueous work-up and 
purification. Taken together, these results illustrate a powerful chemoenzymatic platform 
that can be applied toward creating libraries of compounds likely to be useful in both 
biological studies and glycolipidomic profiling.
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In summary, the presence of α-cholesteryl glycosides in H. pylori was first reported in 
1995.8 Shortly thereafter, α-cholesteryl glucosyl transferase was identified as the enzyme 
responsible for making CG.19,20 While this enzyme is imbedded in the cell wall, presumably 
it loads UDP-Glc from the cytoplasm of H. pylori, which is then combined with 
extracellular cholesterol depleted from host membrane.12 CG appears to be the substrate for 
an enzyme that transfers a tetradecanoic acid donor to the C-6 hydroxyl to form α-CAG but 
that enzyme and the exact acyl donor are yet to be identified.20 Curiously, lyso-
phosphoglycerolipid biosynthesis is correlated with increased α-CAG lipid content 
suggesting that at least some of the fatty acid donor may derive from 
phosphoglycerolipids.21 Moreover, H. pylori isolated from individuals with ulcer disease 
have increased levels of lyso-phosphoglycerolipids.22 Understanding the specific role of α-
CAG in this process and H. pylori infection in general has been hindered due to difficulties 
in isolating ample quantities of pure material from natural sources.
To address this unmet need, herein we have communicated the first total synthesis of α-
CAG using a three-step chemoenzymatic synthesis. The regioselective enzymatic acylation 
was carried out on free glucose in organic solvent and required relatively small amounts of 
enzyme compared to earlier reported procedures. The glycosylation was carried out under 
microwave conditions to shorten reaction times from one or two days to just hours.15 The 
glycosylation does not require TBAI to afford α-linked product, but TBAI does enhance the 
α-selectivity. In contrast, activation of the iodide with AgOTf affords β-CAG. The synthesis 
of both α- and βCAG can now be achieved in reasonably large quantities (>250 mg batches) 
making these compounds available to the biological community. It is our hope that access to 
these important biomarkers will facilitate studies directed toward understanding the roles of 
cholesteryl glycosides in bacterial infections.
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Structures of H. pylori cholesteryl glycosides.
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Unwanted acceptor transilylation side reaction.
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Stereoselective synthesis of α-CAG and β-CAG.
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Table 1
Regioselective Acylation using Novozym 435.
Entry Novozym 435 Vinyl Ester (Equiv.) % Yield
1 250 mg 6 88
2 50 mg 6 87
3 25 mg 6 94
4 10 mg 6 90
5 3 mg 6 93
6 10 mg 3 89
7 10 mg 2 23
8 10 mg 1 31
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